摘要
阿比特龙(商品名:ZYTIGA)是作用于17α-羟化酶/C17,20裂解酶的一种雄激素生物合成抑制剂,主要用于治疗转移性去势抵抗性前列腺癌(mCRPC)。近年来,阿比特龙的药动学、药效学及其临床治疗进展期mCRPC的有效性得到进一步阐明,阿比特龙潜在不良反应和新的临床应用也陆续报道。本文对阿比特龙的药理作用及其临床研究进展作一综述。
Abiraterone（ZYTIGA ） is a biosynthesis inhibitor of androgen signaling axis by acting on 17α- hydroxylase and C17, 20-lyase. It is indicated for the treatment of patients with metastatic castration- resistant prostate cancer（ mCRPC）. In recent years, the pharmacokinetics, pharmacodynamics of abiraterone and its clinical effectiveness for treatment of mCRPC has been further elucidated. Potential adverse reactions and new clinical application of abiraterone has also been reported. The pharmacological effects of abiraterone and its clinical research progress were reviewed in this paper.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2017年第2期65-70,共6页
Chinese Journal of New Drugs and Clinical Remedies
关键词
阿比特龙
前列腺肿瘤
药理作用
治疗
临床研究性
药物相互作用
abiraterone
prostate neoplasms
pharmacologic actions
therapies
investigational
drug interactions
